TG Therapeutics (TGTX) Stock Sinks As Profit Shrinks Behind BRIUMVI Growth
TG Therapeutics (TGTX) shares fell about 11% the day after earnings, as profit declined despite growth tied to BRIUMVI. The company reported Q2 2026 revenue of about $240.3M (up from $141.1M) and BRIUMVI revenue of about $228M, but net income fell to $7.8M and EPS to just over $0.05. Management cited manufacturing charges.
How this was made
The 30-second read
Why it matters
The key trading issue is earnings quality. Despite strong BRIUMVI revenue, heavy manufacturing-related charges compressed net income and EPS, and management guided to continued similar expenses in 2026.
Market read
Investors are likely repricing TGTX based on the gap between strong product revenue growth and weaker reported earnings due to manufacturing cost structure.
What to watch
The article emphasizes reported net income sensitivity to charges but does not quantify cash flow, balance-sheet runway, or whether adjusted profitability is improving alongside scale.
Background
TG Therapeutics is a commercial-stage biopharma focused on B-cell mediated diseases, with BRIUMVI as the core multiple sclerosis franchise.
Ticker impact
TG Therapeutics shares fell about 11% the day after earnings as net income dropped to $7.8M and EPS to ~$0.05 despite BRIUMVI revenue near $228M.
Near-term downside bias as investors reprice cost structure and earnings quality; volatility likely until 2026 manufacturing expense trajectory is clarified.
The article cites specific profit compression metrics (net income and EPS down ~72% and ~71%) and management guidance for ~$100M of similar 2026 manufacturing expenses, which directly challenges the high-margin growth narrative.
Market effects
Highlights how manufacturing scale-up and secondary-source/subcutaneous execution can quickly pressure reported margins in biotech, even when product revenue grows.
Primarily US small/mid-cap biotech sentiment, with Nasdaq-listed momentum affected by earnings-driven repricing.
Limited direct global spillover, but reinforces investor focus on earnings quality and cost-to-serve for MS franchises internationally.
Counterpoint
The BRIUMVI revenue growth and raised U.S. guidance (to $890M-$905M) suggest the commercial engine is working; margin compression may be temporary as manufacturing charges normalize.
Key entities
- public_companyTG Therapeutics
Nasdaq-listed biopharmaceutical company; stock dropped ~11% after earnings due to margin pressure tied to BRIUMVI manufacturing charges.
- productBRIUMVI
Multiple sclerosis drug whose U.S. revenue and gross margin are cited as strong, but whose manufacturing charges are pressuring reported profits.
